New platform for an accurate diagnosis and staging of cancer with 'liquid biopsy'
Conventional cancer biopsies rely on invasive methods to take samples from a tumour's tissues. The sample is used for histological analysis for the clinical diagnosis, and for identification of prognostic and therapeutic targets. Circulating cell-free ribonucleic acids (ccfRNAs) have opened the door to a non-invasive alternative – liquid biopsy. However, despite extensive academic and clinical research, ccfRNAs have not yet entered the field of clinical diagnostics. This is in part because the current analytical methods are unsatisfactory, meaning that ccfRNA detection remains challenging, costly, and based on elaborate multi-step sample preparations. The EU-funded diaRNAgnosis project brings together a pan-European, multidisciplinary and intersectoral team to deliver a new platform for the direct quantitative measurement of ccfRNA signatures that are specifically and overexpressed in testicular germ cell tumour and prostate cancer.
Call for proposal
See other projects for this call
Funding SchemeMSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)